![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hazard Alert! Sinequan® (doxepin)From the April 11, 1996 issue of MSA Acute Care Edition Newsletter
Yesterdays ISMP Medication Safety Alert! (April 10,
1996) described a medication error which involved
confusion between one of the new protease inhibitors, ritonavir,
and Retrovir® (zidovudine), an established
antiretroviral.
In many cases, the drugs are being prescribed before staff
has had adequate time to familiarize themselves
with the drugs and nomenclature. In order to prevent additional
errors, it is important that physicians,
nurses, and pharmacists be aware of the new products. We recommend
that hospitals alert appropriate staff through memos or newsletters.
Further, until these drugs become well established, we also
recommend that prescribers use both brand and generic names
for orders and that the names be printed. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||